Navigation Links
Bayer HealthCare Introduces First Mobile Application to Assist Hemophilia A Patients in Managing Their Treatment
Date:6/28/2010

WAYNE, N.J., June 28 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals today launched FactorTrack™, the first customizable mobile application for people with hemophilia A.  FactorTrack is a free, personal and interactive mobile application that helps make it easier to track and record hemophilia factor VIII infusions.  

FactorTrack captures dosing history, frequency and locations of bleeds.  It allows people with hemophilia A to customize their infusion schedule based on their prescribed regimen, view their infusion history and, with an Internet connection, display an alert when it's time for the next infusion.  It also gives patients the option of emailing infusion and bleed history to themselves or their healthcare team if email is configured on their device.  Further, FactorTrack links people with hemophilia A to educational tools and online resources.  

Any person who treats his or her bleeds with factor VIII infusions can use FactorTrack, regardless of the specific product or therapy.  For those on a prophylaxis (preventive) regimen, the application offers a reminder system to help make it easier to remember when to infuse.  For those who infuse factor VIII on demand (when needed), the application serves as a diary to record bleeds and infusions.  

"FactorTrack is the latest innovation from Bayer that illustrates our ongoing commitment to helping enhance the lives of people who live with bleeding disorders," said Paul Bedard, vice president and general manager, Hematology, Bayer HealthCare Pharmaceuticals Inc.  "We worked alongside the hemophilia community, physical therapists and physical educators to develop the application in response to the needs of people with hemophilia A."

Designed to be compatible with a number of smart phone platforms, FactorTrack is available today on an iPhone, iPod touch or iPad.  People can get information about downloading FactorTrack by going to LivingWithHemophilia.com/FactorTrack.  In the near future, FactorTrack will be made available on other smart phones and the Web.

Bayer doesn't collect personal information when people use the FactorTrack application.  People can use the application without entering information that identifies them.  Recorded data are completely private and will only be stored on a personal iPhone or iPod touch.

About Hemophilia A

Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs.  Approximately one in 5,000 males born in the United States has hemophilia.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals operation of Bayer HealthCare, an affiliate of Bayer AG.  One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the United States, Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, Hematology/Neurology, and Oncology.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

BAYER and the Bayer Cross are registered trademarks and FactorTrack is a trademark of Bayer.

iPhone and iPod touch are registered trademarks and iPad is a trademark of Apple.


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
2. Bayer Sues Teva and Barr for False Advertising and Patent Infringement in Connection with Tevas Generic Oral Contraceptive Gianvi™
3. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
4. Bayer Diabetes Care Introduces DIDGET In the US
5. FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
6. Bayers A1CNow(R) SELFCHECK At-Home A1C System Now Available In Local Pharmacies
7. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
8. Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels
9. Bayer Express Your Simple Win Creativity Contest Grand Prize Winners Announced
10. Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
11. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
Breaking Medicine Technology:
(Date:2/13/2016)... , ... February 13, 2016 , ... Many individuals looking ... protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved into ... once more, but without the high-carb repercussions. IsoPasta has 30 grams of protein ...
(Date:2/13/2016)... ... 2016 , ... When an Au Pair comes all the way around the world ... for and they are often worried things won’t go well. More often than not, however, ... Au Pair of the Year winner’s all commented how their Au Pairs have become a ...
(Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical ... in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the ... products in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a leader in cloud ... Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. ... their small and medium business (SMB) clients. , In recent years, ...
Breaking Medicine News(10 mins):